Search

Your search keyword '"Rouyer, Magali"' showing total 127 results
Start Over Author "Rouyer, Magali"
127 results on '"Rouyer, Magali"'

8. Epidemiology of metastatic castration-resistant prostate cancer: A first estimate of incidence and prevalence using the French nationwide healthcare database

Author

Thurin, Nicolas H., Rouyer, Magali, Gross-Goupil, Marine, Rebillard, Xavier, Soulié, Michel, Haaser, Thibaud, Roumiguié, Mathieu, Le Moulec, Sylvestre, Capone, Camille, Pierrès, Marie, Lamarque, Stéphanie, Jové, Jérémy, Bignon, Emmanuelle, Droz-Perroteau, Cécile, Moore, Nicholas, and Blin, Patrick

Published
2020
Full Text
View/download PDF

10. Intra-database validation of case-identifying algorithms using reconstituted electronic health records from healthcare claims data

Author

Thurin, Nicolas H., Bosco-Levy, Pauline, Blin, Patrick, Rouyer, Magali, Jové, Jérémy, Lamarque, Stéphanie, Lignot, Séverine, Lassalle, Régis, Abouelfath, Abdelilah, Bignon, Emmanuelle, Diez, Pauline, Gross-Goupil, Marine, Soulié, Michel, Roumiguié, Mathieu, Le Moulec, Sylvestre, Debouverie, Marc, Brochet, Bruno, Guillemin, Francis, Louapre, Céline, Maillart, Elisabeth, Heinzlef, Olivier, Moore, Nicholas, and Droz-Perroteau, Cécile

Published
2021
Full Text
View/download PDF

11. Patterns of Use, Safety, and Effectiveness of Targeted Therapies in First-Line Treatment of Metastatic Colorectal Cancer According to Age: The STROMBOLI Cohort Study

Author

Smith, D., Tubiana-Mathieu, N., Michel, P., Guimbaud, R., Becouarn, Y., Viret, F., Larregain-Fournier, D., Botreau, Y., Texereau, P., Auby, D., Gautier-Felizot, L., Loury-Larivière, I., Brudieux, E., Cany, L., Lecaille, C., Jaubert, D., Guichard, P., Bernard, O., Vives, L., Taoubi, N., Martinez, M., Burki, F., Roque, I., Thouveny, F., Gaspard, M.H., Gouverneur, Amandine, Coutureau, Juliette, Jové, Jérémy, Rouyer, Magali, Grelaud, Angela, Duc, Sophie, Gérard, Stéphane, Smith, Denis, Ravaud, Alain, Droz, Cécile, Bernard, Marie-Agnès, Lassalle, Régis, Forrier-Réglat, Annie, and Noize, Pernelle

Published
2019
Full Text
View/download PDF

15. Overall survival with cetuximab every-2-weeks versus standard once-weekly administration schedule for first-line treatment of RAS wild-type metastatic colorectal cancer in patients with left- and right-sided primary tumour location

Author

Kasper, Stefan, primary, Foch, Caroline, additional, Esser, Regina, additional, Lamy, Francois-Xavier, additional, Zhang, Aimar, additional, Cheng, Ann-Lii, additional, Rouyer, Magali, additional, Brodowicz, Thomas, additional, and Zielinski, Christoph, additional

Published
2023
Full Text
View/download PDF

17. Real‐life patterns of use, safety and effectiveness of sunitinib in first‐line therapy of metastatic renal cell carcinoma: the SANTORIN cohort study

Author

Noize, Pernelle, Grelaud, Angela, Bay, Jacques‐Olivier, Chevreau, Christine, Gross‐Goupil, Marine, Culine, Stéphane, Ferrière, Jean‐Marie, Moulin, Flore, Robinson, Philip, Balestra, Aurelie, Lamarque, Stéphanie, Bernard, Marie‐Agnès, Lassalle, Régis, Rouyer, Magali, Droz‐Perroteau, Cécile, Moore, Nicholas, Fourrier‐Réglat, Annie, and Ravaud, Alain

Published
2017
Full Text
View/download PDF

18. Secondary Metastases Resection After Bevacizumab Plus Irinotecan-Based Chemotherapy in First-Line Therapy of Metastatic Colorectal Cancer in a Real-Life Setting: Results of the ETNA Cohort

Author

Rouyer, Magali, Smith, Denis, Laurent, Christophe, Becouarn, Yves, Guimbaud, Rosine, Michel, Pierre, Tubiana-Mathieu, Nicole, Balestra, Aurélie, Jové, Jérémy, Robinson, Philip, Noize, Pernelle, Moore, Nicholas, Ravaud, Alain, Fourrier-Réglat, Annie, and on behalf of the ETNA study group

Published
2016
Full Text
View/download PDF

19. Abiraterone acetate versus docetaxel for metastatic castration-resistant prostate cancer: a cohort study within the French nationwide claims database

Author

Thurin, Nicolas H., primary, Rouyer, Magali, additional, Jové, Jérémy, additional, Gross-Goupil, Marine, additional, Haaser, Thibaud, additional, Rébillard, Xavier, additional, Soulié, Michel, additional, de Pouvourville, Gérard, additional, Capone, Camille, additional, Bazil, Marie-Laure, additional, Messaoudi, Fatiha, additional, Lamarque, Stéphanie, additional, Bignon, Emmanuelle, additional, Droz-Perroteau, Cécile, additional, Moore, Nicholas, additional, and Blin, Patrick, additional

Published
2022
Full Text
View/download PDF

22. The Presence of Strong Instruments in Comparative Effectiveness Studies and How to Mitigate in Propensity Score Analyses: A Case Study in Oncology

Author

Thurin, Nicolas, primary, Jové, Jérémy, additional, Lassalle, Régis, additional, Rouyer, Magali, additional, Lamarque, Stéphanie, additional, Bosco-Levy, Pauline, additional, Segalas, Corentin, additional, Schneeweiss, Sebastian, additional, Blin, Patrick, additional, and Droz-Perroteau, Cécile, additional

Published
2022
Full Text
View/download PDF

23. Applying Sequence Clustering Methods to Characterize Healthcare Pathways of Patients at Different Prostate Cancer Stages in the French Nationwide Healthcare Database

Author

Baulain, Roméo, primary, Jové, Jérémy, additional, Sakr, Dunia, additional, Gross-Goupil, Marine, additional, Rouyer, Magali, additional, Puel, Marius, additional, Blin, Patrick, additional, Droz-Perroteau, Cécile, additional, Lassalle, Régis, additional, and Thurin, Nicolas, additional

Published
2022
Full Text
View/download PDF

24. Additional file 1 of Intra-database validation of case-identifying algorithms using reconstituted electronic health records from healthcare claims data

Author

Thurin, Nicolas H., Bosco-Levy, Pauline, Blin, Patrick, Rouyer, Magali, Jové, Jérémy, Lamarque, Stéphanie, Lignot, Séverine, Lassalle, Régis, Abouelfath, Abdelilah, Bignon, Emmanuelle, Diez, Pauline, Gross-Goupil, Marine, Soulié, Michel, Roumiguié, Mathieu, Le Moulec, Sylvestre, Debouverie, Marc, Brochet, Bruno, Guillemin, Francis, Louapre, Céline, Maillart, Elisabeth, Heinzlef, Olivier, Moore, Nicholas, and Droz-Perroteau, Cécile

Abstract

Additional file 1: Algorithm for the identification of multiple sclerosis relapses.

Published
2021
Full Text
View/download PDF

25. Additional file 2 of Intra-database validation of case-identifying algorithms using reconstituted electronic health records from healthcare claims data

Author

Thurin, Nicolas H., Bosco-Levy, Pauline, Blin, Patrick, Rouyer, Magali, Jové, Jérémy, Lamarque, Stéphanie, Lignot, Séverine, Lassalle, Régis, Abouelfath, Abdelilah, Bignon, Emmanuelle, Diez, Pauline, Gross-Goupil, Marine, Soulié, Michel, Roumiguié, Mathieu, Le Moulec, Sylvestre, Debouverie, Marc, Brochet, Bruno, Guillemin, Francis, Louapre, Céline, Maillart, Elisabeth, Heinzlef, Olivier, Moore, Nicholas, and Droz-Perroteau, Cécile

Abstract

Additional file 2: Algorithm performance indicators before setting adjustment resulting from expert inputs.

Published
2021
Full Text
View/download PDF

26. Patterns of quadruple therapy use including bismuth for Helicobacter pylori eradication: A cohort study in the French national claims database

Author

Blin, Patrick, Rouyer, Magali, Guiard, Estelle, Zerbib, F., DIQUET, B., MEGRAUD, F., Tison, F., Abouelfath, Abdelilah, Lassalle, R., DROZ-PERROTEAU, Cecile, Moore, Nicholas, Bordeaux population health (BPH), and Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
surgical procedures, operative, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie
Abstract

BACKGROUND: Quadruple therapy using a single capsule formulation of bismuth, metronidazole and tetracycline (BMT; Pylera®), associated with omeprazole for the eradication of Helicobacter pylori, represents the reintroduction of bismuth in France after 40 years. OBJECTIVE: To describe the real-life patterns of use of BMT following a request from the French health authorities. METHODS: Patients with a first BMT dispensing (index date, ID), with one year of data before and after ID, were identified in the French nationwide claims database 1/97 sample. Misuse of BMT was defined as dispensing>1 pack of BMT at ID or absence of a diagnostic test in the preceding year. RESULTS: In total, 540 patients were included. Prescribers were gastroenterologists (n=243; 45%) and general practitioners (n=160; 30%). A proton pump inhibitor was co-dispensed to 504 patients (96%). Ten patients (2%) had contraindications to BMT. Fifty-nine patients (11%) met the misuse criteria: ten (2%) were dispensed>1 pack of BMT and 49 (9%) had not had a diagnostic test for H. pylori in the previous year. During follow-up, 27 patients (5%) required retreatment (treatment failure). CONCLUSION: In this real-life study, most patients were dispensed only one pack of BMT, consistent with recommendations. Misuse related principally to the absence of prior diagnostic test for H. pylori.

Published
2020
Full Text
View/download PDF

28. Impact of treatment sequence on survival outcome in patients with a second treatment line for metastatic castration-resistant prostate cancer: A new user design in the French nationwide claims database.

Author

Gross-Goupil, Marine, primary, Thurin, Nicolas H., additional, Rouyer, Magali, additional, Haaser, Thibaud, additional, Rebillard, Xavier, additional, Soulie, Michel, additional, de Pouvourville, Gérard, additional, Messaoudi, Fatiha, additional, Capone, Camille, additional, Bignon, Emmanuelle, additional, Jové, Jérémy, additional, Lamarque, Stéphanie, additional, Droz-Perroteau, Cécile, additional, Moore, Nicholas, additional, and Blin, Patrick, additional

Published
2021
Full Text
View/download PDF

29. Intra-database Validation of Case-identifying Algorithms Using Reconstituted Electronic Health Records From Healthcare Claims Data

Author

Thurin, Nicolas Henri, primary, Bosco-Levy, Pauline, additional, Blin, Patrick, additional, Rouyer, Magali, additional, Jové, Jérémy, additional, Lamarque, Stéphanie, additional, Séverine, Lignot, additional, Lassalle, Régis, additional, Abouelfath, Abdelilah, additional, Emmanuelle, Bignon, additional, Pauline, Diez, additional, Gross-Goupil, Marine, additional, Soulié, Michel, additional, Roumiguié, Mathieu, additional, Moulec, Sylvestre Le, additional, Debouverie, Marc, additional, Brochet, Bruno, additional, Guillemin, Francis, additional, Louapre, Céline, additional, Maillart, Elisabeth, additional, Heinzlef, Olivier, additional, Moore, Nicholas, additional, and Cécile, Droz-Perroteau, additional

Published
2021
Full Text
View/download PDF

30. Contamination interne du personnel infirmier par les médicaments anticancéreux : étude multicentrique Française

Author

Villa, Antoine, primary, Molimard, Mathieu, additional, Bignon, Emmanuelle, additional, Martinez, Béatrice, additional, Sakr, Dunia, additional, Lassalle, Régis, additional, Rouyer, Magali, additional, Mathoulin-Pelissier, Simone, additional, Baldi, Isabelle, additional, Verdun-Esquer, Catherine, additional, and Raffin, Mireille Canal, additional

Published
2020
Full Text
View/download PDF

31. Effectiveness of first‐line cetuximab in wild‐type RAS metastatic colorectal cancer according to tumour BRAF mutation status from the EREBUS cohort

Author

Rouyer, Magali, primary, François, Eric, additional, Sa Cunha, Antonio, additional, Monnereau, Alain, additional, Bignon, Emmanuelle, additional, Jové, Jérémy, additional, Lassalle, Régis, additional, Droz‐Perroteau, Cécile, additional, Moore, Nicholas, additional, Noize, Pernelle, additional, Fourrier‐Réglat, Annie, additional, and Smith, Denis, additional

Published
2020
Full Text
View/download PDF

32. Survival outcome in patients with metastatic castration-resistant prostate cancer according to first-line treatment.

Author

Gross-Goupil, Marine, primary, Thurin, Nicolas H., additional, Rouyer, Magali, additional, Jové, Jérémy, additional, Haaser, Thibaud, additional, Rebillard, Xavier, additional, Soulie, Michel, additional, de Pouvourville, Gérard, additional, Pierrès, Marie, additional, Capone, Camille, additional, Lamarque, Stéphanie, additional, Bignon, Emmanuelle, additional, Droz-Perroteau, Cécile, additional, Moore, Nicholas, additional, and Blin, Patrick, additional

Published
2020
Full Text
View/download PDF

34. Study protocol for the assessment of nurses internal contamination by antineoplastic drugs in hospital centres: a cross-sectional multicentre descriptive study

Author

Villa, Antoine, Molimard, Mathieu, Bignon, Emmanuelle, Martinez, Béatrice, Rouyer, Magali, Mathoulin-Pelissier, Simone, Baldi, Isabelle, Verdun-Esquer, Catherine, Canal-Raffin, Mireille, Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), CIC Bordeaux, Université Bordeaux Segalen - Bordeaux 2-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Pellegrin, CHU Bordeaux [Bordeaux]-Groupe hospitalier Pellegrin, and Admin, Oskar

Subjects
occupational & industrial medicine, education, Antineoplastic Agents, Nursing Staff, Hospital, nurses, antineoplastic drugs, Occupational Exposure, Protocol, Humans, Multicenter Studies as Topic, Ifosfamide, Prospective Studies, Cyclophosphamide, Occupational and Environmental Medicine, Oncology Nursing, urine, Observational Studies as Topic, Cross-Sectional Studies, Methotrexate, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, Doxorubicin, Research Design, [SDV.SP.PHARMA] Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology, biomonitoring, [SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Fluorouracil, France, Self Report, Biomarkers, Environmental Monitoring
Abstract

International audience; INTRODUCTION: Antineoplastic drugs (AD) are potentially carcinogenic and/or reprotoxic molecules. Healthcare professionals are increasingly exposed to these drugs and can be potentially contaminated by them. Internal contamination of professionals is a key concern for occupational physicians in the assessment and management of occupational risks in healthcare settings. Objectives of this study are to report AD internal contamination rate in nursing staff and to identify factors associated with internal contamination.METHODS AND ANALYSIS: This trial will be conducted in two French hospital centres: University Hospital of Bordeaux and IUCT-Oncopole of Toulouse. The target population is nurses practicing in one of the fifteen selected care departments where at least one of the five studied AD is handled (5-fluorouracil, cyclophosphamide, doxorubicin, ifosfamide, methotrexate). The trial will be conducted with the following steps: (1) development of analytical methods to quantify AD urine biomarkers, (2) study of the workplace and organization around AD in each care department (transport and handling, professional practices, personal and collective protection equipments available) (3) development of a self-questionnaire detailing professional activities during the day of inclusion, (4) nurses inclusion (urine samples and self-questionnaire collection), (5) urine assays, (6) data analysis.ETHICS AND DISSEMINATION: The study protocol has been approved by the French Advisory Committee on the Treatment of Information in Health Research (CCTIRS) and by the French Data Protection Authority (CNIL). Following the opinion of the Regional Committee for the Protection of Persons, this study is outside the scope of the provisions governing biomedical research and routine care (n degrees 2014/87). The results will be submitted to peer-reviewed journals and reported at suitable national and international meetings.TRIAL REGISTRATION NUMBER: NCT03137641.

Published
2019
Full Text
View/download PDF

35. Patterns of Use, Safety, and Effectiveness of Targeted Therapies in First-Line Treatment of Metastatic Colorectal Cancer According to Age: The STROMBOLI Cohort Study

Author

Gouverneur, Amandine, primary, Coutureau, Juliette, additional, Jové, Jérémy, additional, Rouyer, Magali, additional, Grelaud, Angela, additional, Duc, Sophie, additional, Gérard, Stéphane, additional, Smith, Denis, additional, Ravaud, Alain, additional, Droz, Cécile, additional, Bernard, Marie-Agnès, additional, Lassalle, Régis, additional, Forrier-Réglat, Annie, additional, Noize, Pernelle, additional, Smith, D., additional, Tubiana-Mathieu, N., additional, Michel, P., additional, Guimbaud, R., additional, Becouarn, Y., additional, Viret, F., additional, Larregain-Fournier, D., additional, Botreau, Y., additional, Texereau, P., additional, Auby, D., additional, Gautier-Felizot, L., additional, Loury-Larivière, I., additional, Brudieux, E., additional, Cany, L., additional, Lecaille, C., additional, Jaubert, D., additional, Guichard, P., additional, Bernard, O., additional, Vives, L., additional, Taoubi, N., additional, Martinez, M., additional, Burki, F., additional, Roque, I., additional, Thouveny, F., additional, and Gaspard, M.H., additional

Published
2019
Full Text
View/download PDF

36. Effectiveness of first‐line cetuximab in wild‐type RAS metastatic colorectal cancer according to tumour BRAF mutation status from the EREBUS cohort.

Author

Rouyer, Magali, François, Eric, Sa Cunha, Antonio, Monnereau, Alain, Bignon, Emmanuelle, Jové, Jérémy, Lassalle, Régis, Droz‐Perroteau, Cécile, Moore, Nicholas, Noize, Pernelle, Fourrier‐Réglat, Annie, and Smith, Denis

Subjects
*CETUXIMAB, *HOSPITAL central service departments, *BRAF genes, *METASTASIS, *MOLECULAR genetics, *PROGRESSION-free survival, *GENDER
Abstract

Aims: Poor efficacy has been reported for patients with BRAF mutations for metastatic colorectal cancer (mCRC). Methods: EREBUS is a French cohort study of wild‐type (wt) KRAS unresectable mCRC patients initiating a first‐line treatment with cetuximab from 2009 to 2010, followed for two years (five years for vital status). Molecular genetics platforms have provided additional RAS and BRAF mutation testing results. Progression‐free survival (PFS) and overall survival (OS) were assessed according to tumour mutation (mt) status: RASmt/BRAFany, RASwt/BRAFmt and RASwt/BRAFwt. Multivariate Cox analyses were used to evaluate association between mutation status and death or progression. Results: A total of 389 patients were included in 65 centres and with a known tumour mutation status: 64 RASmt/BRAFany (21%), 33 RASwt/BRAFmt (13%) and 213 RASwt/BRAFwt (87%). Respective baseline characteristics were: median age 65, 64 and 63 years, male gender 63%, 64% and 69%, Eastern Cooperative Oncology Group performance status ≤ 1 75%, 76% and 79%, and liver‐only metastases 39%, 33% and 40%. Median progression‐free survival was 8.0 months [5.9–9.3] for patients with RASmt/BRAFany, 6.0 months [2.3–7.2] for patients with RASwt/BRAFmt, and 10.4 months [9.5–11.0] for patients with RASwt/BRAFwt. Respectively, median overall survival was 18.4 months [10.9–23.3], 9.7 months [6.9–16.6] and 29.3 months [26.3–36.1]. In multivariate analyses, progression (HR = 2.71 [1.79–4.10]) and death (HR = 2.79 [1.81–4.30]) were more likely for RASwt/BRAFmt vs RASwt/BRAFwt patients. Conclusions: BRAF mutations were associated with markedly poorer outcomes in initially unresectable RASwt mCRC patients treated by cetuximab in first‐line treatment. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

37. Cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC): Real-life use, effectiveness, safety, and quality of life (QoL) in the FUJI cohort.

Author

Oudard, Stephane, primary, Fizazi, Karim, additional, Joly, Florence, additional, Tubach, Florence, additional, Rouyer, Magali, additional, Lamarque, Stéphanie, additional, Guiard, Estelle, additional, Balestra, Aurélie, additional, Lacueille, Clémentine, additional, Jové, Jérémy, additional, Droz-Perroteau, Cécile, additional, Fourrier-Réglat, Annie, additional, and Moore, Nicholas, additional

Published
2018
Full Text
View/download PDF

38. Outcomes of cetuximab in 1st-line therapy for metastatic colorectal cancer (mCRC) according to tumor RAS/BRAF mutation (mt) status in the EREBUS cohort.

Author

Smith, Denis Michel, primary, Rouyer, Magali, additional, Francois, Eric, additional, Sa Cunha, Antonio, additional, Monnereau, Alain, additional, Yon, Edwige, additional, Bignon, Emmanuelle, additional, Droz-Perroteau, Cécile, additional, Noize, Pernelle, additional, Moore, Nicholas, additional, and Fourrier-Réglat, Annie, additional

Published
2018
Full Text
View/download PDF

39. Patterns of quadruple therapy use including bismuth for Helicobacter pylorieradication: A cohort study in the French national claims database

Author

Blin, Patrick, Rouyer, Magali, Guiard, Estelle, Zerbib, Frank, Diquet, Bertrand, Mégraud, Francis, Tison, François, Abouelfath, Abdelilah, Lassalle, Régis, Droz-Perroteau, Cécile, and Moore, Nicholas

Abstract

Quadruple therapy using a single capsule formulation of bismuth, metronidazole and tetracycline (BMT; Pylera®), associated with omeprazole for the eradication of Helicobacter pylori, represents the reintroduction of bismuth in France after 40 years.

Published
2021
Full Text
View/download PDF

40. Outcomes according to tumor RAS and BRAF mutation status in patients treated with cetuximab in 1st-line treatment of unresectable metastatic colorectal cancer (mCRC): Updated results from EREBUS cohort

Author

Smith, Denis, primary, Sa-cunha, Antonio, additional, Rouyer, Magali, additional, François, Eric, additional, Monnereau, Alain, additional, Yon, Edwige, additional, Bignon, Emmanuelle, additional, Noize, Pernelle, additional, Droz-Perroteau, Cécile, additional, Moore, Nicholas, additional, and Fourrier-réglat, Annie, additional

Published
2017
Full Text
View/download PDF

41. Overall and progression-free survival with cabazitaxel in metastatic castration-resistant prostate cancer in routine clinical practice: the FUJI cohort.

Author

Rouyer, Magali, Oudard, Stéphane, Joly, Florence, Fizazi, Karim, Tubach, Florence, Jove, Jérémy, Lacueille, Clémentine, Lamarque, Stéphanie, Guiard, Estelle, Balestra, Aurélie, Droz-Perroteau, Cécile, Fourrier-Reglat, Annie, Moore, Nicholas, on behalf of the FUJI Investigators, Abdiche, Samir, Angellier, Elisabeth, Beal-Ardisson, Dominique, Bera, Guillaume, Berdah, Jean-François, and Bernard, Olivier

Abstract

Background: Cabazitaxel is a treatment of metastatic castration-resistant prostate cancer (mCRPC) after docetaxel failure. The FUJI cohort aimed to confirm the real-life overall and progression-free survival (OS, PFS) and safety of cabazitaxel.Methods: Multicentre, non-interventional cohort of French mCRPC patients initiating cabazitaxel between 2013 and 2015, followed 18 months.Results: Four hundred one patients were recruited in 42 centres. At inclusion, median age was 70, main metastatic sites were bones (87%), lymph nodes (42%) and visceral (20%). 18% had cabazitaxel in 2nd-line treatment, 39% in 3rd-line and 43% in 4th-line or beyond. All had prior docetaxel, and 82% prior abiraterone, enzalutamide or both. Median duration of cabazitaxel treatment was 3.4 months. Median OS from cabazitaxel initiation was 11.9 months [95% CI: 10.1-12.9]. In multivariate analyses, grade ≥ 3 adverse events, visceral metastases, polymedication, and >5 bone metastases were associated with a shorter OS. Main grade ≥ 3 adverse events were haematological with 8% febrile neutropenia.Conclusion: Real-life survival with cabazitaxel in FUJI was shorter than in TROPIC (pivotal trial, median OS 15.1 months) or PROSELICA (clinical trial 20 vs 25 mg/m2, median OS, respectively, 13.4 and 14.5 months). There was no effect of treatment-line on survival. No unexpected adverse concerns were identified.Study Registration: It was registered with the European Medicines Agency EUPASS registry, available at www.encepp.eu, as EUPAS10391. It has been approved as an ENCEPP SEAL study. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

43. Oncopharmaco-épidémiologie : à propos de 10ans d’expérience d’une plate-forme de recherche française

Author

Rouyer, Magali, primary, Grelaud, Angela, additional, Noize, Pernelle, additional, Droz-Perroteau, Cécile, additional, Lassalle, Régis, additional, Jové, Jérémy, additional, Bernard, Marie-Agnès, additional, Gouverneur, Amandine, additional, Bosco-Lévy, Pauline, additional, Bezin, Julien, additional, Smith, Denis, additional, Ravaud, Alain, additional, Moore, Nicholas, additional, and Fourrier-Réglat, Annie, additional

Published
2016
Full Text
View/download PDF

44. Under Prescription of Target Therapy in First-Line Metastatic Colorectal Cancer in Elderly People: A Cohort Study in a French Center

Author

Noize Pernelle, Daste Amaury, Ravaud Alain, Smith Denis, Terrebonne Eric, Fourrier-réglat Annie, and Rouyer Magali

Subjects
Oncology, medicine.medical_specialty, business.industry, Colorectal cancer, First line, Hematology, medicine.disease, Internal medicine, medicine, Elderly people, Center (algebra and category theory), Target therapy, Medical prescription, business, Cohort study
Published
2014
Full Text
View/download PDF

45. Cetuximab with Irinotecan or Oxaliplatin for 1St-Line Metastatic Colorectal Cancer: Updated Data of Effectiveness in the Erebus Cohort Compared to Pivotal Trials

Author

Monnereau Alain, Sa-cunha Antonio, Moore Nicholas, Noize Pernelle, François Eric, Annie Fourrier-Réglat, Mitry Emmanuel, Smith Denis, Rouyer Magali, Jové Jérémy, Balestra Aurélie, and Bignon Emmanuelle

Subjects
Oncology, medicine.medical_specialty, biology, Cetuximab, business.industry, Colorectal cancer, Hematology, Erebus, biology.organism_classification, medicine.disease, Oxaliplatin, Irinotecan, Internal medicine, Cohort, medicine, Line (text file), business, medicine.drug
Published
2014
Full Text
View/download PDF

46. Cetuximab with irinotecan or oxaliplatin for first-line metastatic colorectal cancer: Effectiveness in the EREBUS cohort compared to pivotal trials.

Author

Fourrier-Réglat, Annie, primary, Rouyer, Magali, additional, Noize, Pernelle, additional, Bignon, Emmanuelle, additional, Le Monies, Alise, additional, Jove, Jeremy, additional, Monnereau, Alain, additional, Sa Cunha, Antonio, additional, Francois, Eric, additional, Mitry, Emmanuel, additional, and Smith, Denis Michel, additional

Published
2013
Full Text
View/download PDF

47. Surgical resection of liver metastases and survival outcomes in real-life for metastatic colorectal cancer (mCRC) patients treated in front-line with cetuximab (CTX): The EREBUS cohort.

Author

Smith, Denis Michel, primary, Sa Cunha, Antonio, additional, Rouyer, Magali, additional, Noize, Pernelle, additional, Jove, Jeremy, additional, Bignon, Emmanuelle, additional, Le Monies, Alise, additional, Mitry, Emmanuel, additional, Francois, Eric, additional, and Fourrier-Réglat, Annie, additional

Published
2013
Full Text
View/download PDF

48. Patterns and effectiveness of bortezomib use according to age in the VESUVE cohort.

Author

Grelaud, Angela, Fourrier-Réglat, Annie, Fitoussi, Olivier, Facon, Thierry, Jové, Jérémy, Bénichou, Jacques, Robinson, Philip, Marit, Gérald, Rouyer, Magali, Moore, Nicholas, and Noize, Pernelle

Subjects
BORTEZOMIB, MULTIPLE myeloma, DRUG efficacy, OLDER patients, COHORT analysis, PROGRESSION-free survival, PATIENTS, THERAPEUTICS
Abstract

Therapeutical options for older multiple myeloma patients have been improved with the advent of new drugs, yet there is a lack of observational data for such patients. To address this issue, an age-stratified analysis of the VESUVE cohort of bortezomib users was performed. Among the 779 patients included in the analysis, 358 (46%) were aged ≤ 65 years, 282 (36%) were between 65–75 years and 139 (18%) were more than 75 years old. There were few significant differences in treatment parameters across age groups; notably, older patients received a lower dose of bortezomib and more frequently experienced general or administration site conditions, metabolism or nutrition disorders and cardiac disorders. Overall best response rate and progression-free survival were similar across age groups. Taken together, these results indicate that older patients do benefit from bortezomib and that tailored treatment in real-life clinical practice does not compromise effectiveness. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

49. Use of cetuximab (CTX) in first-line therapy of metastatic colorectal cancer (mCRC): Patient characteristics, safety, and effectiveness in the EREBUS cohort.

Author

Smith, Denis, primary, Rouyer, Magali, additional, Mitry, Emmanuel, additional, François, Eric, additional, Monnereau, Alain, additional, Sa Cunha, Antonio, additional, Bignon, Emmanuelle, additional, Le Monies, Alise, additional, Jove, Jeremy, additional, Noize, Pernelle, additional, Moore, Nicholas, additional, and Fourrier-Réglat, Annie, additional

Published
2012
Full Text
View/download PDF

50. Cetuximab in first-line treatment of metastatic colorectal cancer in a real-life setting: Preliminary results of the EREBUS cohort.

Author

Smith, Denis, primary, Rouyer, Magali, additional, Mitry, Emmanuel, additional, Monnereau, Alain, additional, Sa Cunha, Antonio, additional, Bignon, Emmanuelle, additional, Le Monies, Alise, additional, Jove, Jeremy, additional, Noize, P., additional, Moore, Nicholas, additional, and Fourrier-Réglat, Annie, additional

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results